25 XP   0   0   10

Roivant Sciences Ltd
Buy, Hold or Sell?

Let's analyse Roivant together

PenkeI guess you are interested in Roivant Sciences Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Roivant Sciences Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Roivant Sciences Ltd

I send you an email if I find something interesting about Roivant Sciences Ltd.

Quick analysis of Roivant (30 sec.)










What can you expect buying and holding a share of Roivant? (30 sec.)

How much money do you get?

How much money do you get?
$0.02
When do you have the money?
1 year
How often do you get paid?
26.7%

What is your share worth?

Current worth
$7.80
Expected worth in 1 year
$13.82
How sure are you?
26.7%

+ What do you gain per year?

Total Gains per Share
$6.04
Return On Investment
58.3%

For what price can you sell your share?

Current Price per Share
$10.36
Expected price per share
$9.6 - $13.24
How sure are you?
50%

1. Valuation of Roivant (5 min.)




Live pricePrice per Share (EOD)

$10.36

Intrinsic Value Per Share

$-5.12 - $-5.75

Total Value Per Share

$2.68 - $2.05

2. Growth of Roivant (5 min.)




Is Roivant growing?

Current yearPrevious yearGrowGrow %
How rich?$6.5b$1.6b$1b37.7%

How much money is Roivant making?

Current yearPrevious yearGrowGrow %
Making money$1b-$336.4m$1.4b131.1%
Net Profit Margin2,727.7%-4,031.9%--

How much money comes from the company's main activities?

3. Financial Health of Roivant (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#11 / 1016

Most Revenue
#199 / 1016

Most Profit
#3 / 1016

Most Efficient
#13 / 1016

What can you expect buying and holding a share of Roivant? (5 min.)

Welcome investor! Roivant's management wants to use your money to grow the business. In return you get a share of Roivant.

What can you expect buying and holding a share of Roivant?

First you should know what it really means to hold a share of Roivant. And how you can make/lose money.

Speculation

The Price per Share of Roivant is $10.36. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Roivant.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Roivant, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $7.80. Based on the TTM, the Book Value Change Per Share is $1.51 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.25 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Roivant.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps6.0358.3%1.3112.7%-0.39-3.7%0.131.3%0.131.3%
Usd Book Value Change Per Share6.1559.4%1.5114.5%-0.25-2.5%0.525.0%0.525.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share6.1559.4%1.5114.6%-0.25-2.5%0.525.0%0.525.0%
Usd Price Per Share11.23-10.09-5.06-7.32-7.32-
Price to Earnings Ratio0.47--14.61--3.24--8.24--8.24-
Price-to-Total Gains Ratio1.83--937.89--29.12--332.09--332.09-
Price to Book Ratio1.44-4.58-2.51-2.86-2.86-
Price-to-Total Gains Ratio1.83--937.89--29.12--332.09--332.09-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share10.36
Number of shares96
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share1.510.52
Usd Total Gains Per Share1.510.52
Gains per Quarter (96 shares)145.0050.01
Gains per Year (96 shares)580.00200.04
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
115795700200190
23115711501399390
34173617301599590
46231423102798790
57289328902998990
6934713470311981190
71040504050313971390
81246284630315971590
91352075210417971790
101557855790419961990

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.014.00.06.7%1.014.00.06.7%1.014.00.06.7%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%4.08.03.026.7%4.08.03.026.7%4.08.03.026.7%
Dividend per Share3.00.01.075.0%4.00.08.033.3%4.00.011.026.7%4.00.011.026.7%4.00.011.026.7%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%4.08.03.026.7%4.08.03.026.7%4.08.03.026.7%

Fundamentals of Roivant

About Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Fundamental data was last updated by Penke on 2024-03-31 11:44:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Roivant Sciences Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Roivant earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Roivant to the Biotechnology industry mean.
  • A Net Profit Margin of 13,721.6% means that $137.22 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Roivant Sciences Ltd:

  • The MRQ is 13,721.6%. The company is making a huge profit. +2
  • The TTM is 2,727.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ13,721.6%TTM2,727.7%+10,993.8%
TTM2,727.7%YOY-4,031.9%+6,759.7%
TTM2,727.7%5Y-1,314.9%+4,042.7%
5Y-1,314.9%10Y-1,314.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13,721.6%-197.2%+13,918.8%
TTM2,727.7%-210.4%+2,938.1%
YOY-4,031.9%-279.3%-3,752.6%
5Y-1,314.9%-436.8%-878.1%
10Y-1,314.9%-599.3%-715.6%
1.1.2. Return on Assets

Shows how efficient Roivant is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Roivant to the Biotechnology industry mean.
  • 69.7% Return on Assets means that Roivant generated $0.70 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Roivant Sciences Ltd:

  • The MRQ is 69.7%. Using its assets, the company is very efficient in making profit. +2
  • The TTM is 8.5%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ69.7%TTM8.5%+61.2%
TTM8.5%YOY-14.2%+22.6%
TTM8.5%5Y-4.2%+12.7%
5Y-4.2%10Y-4.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ69.7%-13.6%+83.3%
TTM8.5%-12.9%+21.4%
YOY-14.2%-11.9%-2.3%
5Y-4.2%-14.2%+10.0%
10Y-4.2%-16.2%+12.0%
1.1.3. Return on Equity

Shows how efficient Roivant is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Roivant to the Biotechnology industry mean.
  • 83.7% Return on Equity means Roivant generated $0.84 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Roivant Sciences Ltd:

  • The MRQ is 83.7%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 2.2%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ83.7%TTM2.2%+81.5%
TTM2.2%YOY-23.5%+25.7%
TTM2.2%5Y-9.4%+11.6%
5Y-9.4%10Y-9.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ83.7%-17.0%+100.7%
TTM2.2%-16.1%+18.3%
YOY-23.5%-15.4%-8.1%
5Y-9.4%-20.0%+10.6%
10Y-9.4%-21.1%+11.7%

1.2. Operating Efficiency of Roivant Sciences Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Roivant is operating .

  • Measures how much profit Roivant makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Roivant to the Biotechnology industry mean.
  • An Operating Margin of -619.7% means the company generated $-6.20  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Roivant Sciences Ltd:

  • The MRQ is -619.7%. The company is operating very inefficient. -2
  • The TTM is -898.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-619.7%TTM-898.0%+278.3%
TTM-898.0%YOY-3,324.2%+2,426.2%
TTM-898.0%5Y-3,464.0%+2,566.0%
5Y-3,464.0%10Y-3,464.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-619.7%-286.1%-333.6%
TTM-898.0%-224.4%-673.6%
YOY-3,324.2%-288.4%-3,035.8%
5Y-3,464.0%-475.2%-2,988.8%
10Y-3,464.0%-624.7%-2,839.3%
1.2.2. Operating Ratio

Measures how efficient Roivant is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 8.74 means that the operating costs are $8.74 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Roivant Sciences Ltd:

  • The MRQ is 8.742. The company is inefficient in keeping operating costs low. -1
  • The TTM is 9.894. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ8.742TTM9.894-1.152
TTM9.894YOY34.242-24.349
TTM9.8945Y32.993-23.099
5Y32.99310Y32.9930.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.7422.997+5.745
TTM9.8943.247+6.647
YOY34.2423.766+30.476
5Y32.9935.675+27.318
10Y32.9937.857+25.136

1.3. Liquidity of Roivant Sciences Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Roivant is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 27.79 means the company has $27.79 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Roivant Sciences Ltd:

  • The MRQ is 27.794. The company is very able to pay all its short-term debts. +2
  • The TTM is 11.653. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ27.794TTM11.653+16.141
TTM11.653YOY8.004+3.649
TTM11.6535Y8.074+3.579
5Y8.07410Y8.0740.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ27.7943.930+23.864
TTM11.6534.251+7.402
YOY8.0045.436+2.568
5Y8.0746.045+2.029
10Y8.0746.363+1.711
1.3.2. Quick Ratio

Measures if Roivant is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Roivant to the Biotechnology industry mean.
  • A Quick Ratio of 27.50 means the company can pay off $27.50 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Roivant Sciences Ltd:

  • The MRQ is 27.497. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 11.352. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ27.497TTM11.352+16.145
TTM11.352YOY7.700+3.653
TTM11.3525Y7.833+3.519
5Y7.83310Y7.8330.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ27.4973.629+23.868
TTM11.3524.065+7.287
YOY7.7005.397+2.303
5Y7.8335.993+1.840
10Y7.8336.277+1.556

1.4. Solvency of Roivant Sciences Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Roivant assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Roivant to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.10 means that Roivant assets are financed with 10.0% credit (debt) and the remaining percentage (100% - 10.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Roivant Sciences Ltd:

  • The MRQ is 0.100. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.290. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.100TTM0.290-0.191
TTM0.290YOY0.299-0.009
TTM0.2905Y0.211+0.079
5Y0.21110Y0.2110.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1000.332-0.232
TTM0.2900.334-0.044
YOY0.2990.268+0.031
5Y0.2110.366-0.155
10Y0.2110.390-0.179
1.4.2. Debt to Equity Ratio

Measures if Roivant is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Roivant to the Biotechnology industry mean.
  • A Debt to Equity ratio of 12.0% means that company has $0.12 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Roivant Sciences Ltd:

  • The MRQ is 0.120. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.567. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.120TTM0.567-0.447
TTM0.567YOY0.503+0.064
TTM0.5675Y0.361+0.206
5Y0.36110Y0.3610.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1200.381-0.261
TTM0.5670.390+0.177
YOY0.5030.334+0.169
5Y0.3610.434-0.073
10Y0.3610.466-0.105

2. Market Valuation of Roivant Sciences Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Roivant generates.

  • Above 15 is considered overpriced but always compare Roivant to the Biotechnology industry mean.
  • A PE ratio of 0.47 means the investor is paying $0.47 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Roivant Sciences Ltd:

  • The EOD is 0.429. Based on the earnings, the company is cheap. +2
  • The MRQ is 0.465. Based on the earnings, the company is cheap. +2
  • The TTM is -14.613. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.429MRQ0.465-0.036
MRQ0.465TTM-14.613+15.078
TTM-14.613YOY-3.238-11.375
TTM-14.6135Y-8.236-6.377
5Y-8.23610Y-8.2360.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.429-2.315+2.744
MRQ0.465-2.560+3.025
TTM-14.613-2.664-11.949
YOY-3.238-4.122+0.884
5Y-8.236-6.258-1.978
10Y-8.236-6.108-2.128
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Roivant Sciences Ltd:

  • The EOD is -10.375. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -11.246. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -9.887. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-10.375MRQ-11.246+0.871
MRQ-11.246TTM-9.887-1.359
TTM-9.887YOY-5.053-4.834
TTM-9.8875Y-8.190-1.697
5Y-8.19010Y-8.1900.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-10.375-3.067-7.308
MRQ-11.246-3.251-7.995
TTM-9.887-3.545-6.342
YOY-5.053-5.595+0.542
5Y-8.190-8.315+0.125
10Y-8.190-8.708+0.518
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Roivant is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.44 means the investor is paying $1.44 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Roivant Sciences Ltd:

  • The EOD is 1.329. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.440. Based on the equity, the company is underpriced. +1
  • The TTM is 4.582. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD1.329MRQ1.440-0.112
MRQ1.440TTM4.582-3.142
TTM4.582YOY2.506+2.076
TTM4.5825Y2.859+1.723
5Y2.85910Y2.8590.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.3291.905-0.576
MRQ1.4402.111-0.671
TTM4.5822.095+2.487
YOY2.5062.836-0.330
5Y2.8593.443-0.584
10Y2.8593.794-0.935
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Roivant Sciences Ltd.

3.1. Institutions holding Roivant Sciences Ltd

Institutions are holding 62.058% of the shares of Roivant Sciences Ltd.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Qvt Financial LP13.965671.596211254153600
2023-12-31SB INVESTMENT ADVISERS (UK) LTD9.06277.29987303166700
2023-12-31Viking Global Investors LP8.60822.853469368961-4065340-5.536
2023-12-31FMR Inc4.58850.031936976248-1934377-4.9713
2023-12-31Morgan Stanley - Brokerage Accounts2.7210.021721927044261541313.5432
2023-12-31BlackRock Inc2.58180.00620805601308206417.3897
2023-12-31Rubric Capital Management LP2.35784.427319000000850000080.9524
2023-12-31State Street Corporation1.70350.007513727418340662633.0074
2023-12-31Wellington Management Company LLP1.69270.028613640416-1202560-8.1019
2023-12-31Patient Square Capital1.568577.59871263992000
2023-12-31Two Seas Capital LP1.055823.330685082235929917.4918
2023-12-31Baker Bros Advisors LP0.94220.97027593024-4284147-36.0704
2023-12-31Farallon Capital Management, L.L.C.0.91030.4097336000348260090.3773
2023-12-31Vanguard Group Inc0.8780.00177075651147308526.293
2023-12-31Woodline Partners LP0.76340.75136151767-1022486-14.2522
2023-12-31Geode Capital Management, LLC0.68560.006555245763063965.8717
2023-12-31Adage Capital Partners Gp LLC0.65460.12265275000-925000-14.9194
2023-12-31Anchorage Advisors, LLC0.59976.4587483264200
2023-12-31venBio Select Advisor LLC0.57720.7215465116200
2023-09-30Octagon Capital Advisors LP0.54197.8363436700046300011.8596
Total 56.459204.4795454973856+10488265+2.3%

3.2. Funds holding Roivant Sciences Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Fidelity Growth Compy Commingled Pl O1.79020.2011144266224602873.2957
2024-01-31Fidelity Growth Company Fund1.34590.197810845691306510.2834
2023-12-31Vanguard Health Care Inv1.18780.2316957213900
2024-02-29SPDR® S&P Biotech ETF1.06531.240185843691603801.9038
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.60580.05474882047-45219-0.9177
2024-01-31Fidelity Select Biotechnology0.54440.9514387019-134300-2.9704
2023-12-31Morgan Stanley Inst Growth I0.51250.8354130061861682.1308
2023-12-31Morgan Stanley Growth0.51250.835741300613544339.3874
2023-12-31Morgan Stanley Growth SMA0.51250.835741300613544339.3874
2024-02-29iShares Biotechnology ETF0.50490.61194068397-18310-0.448
2024-01-31Fidelity Growth Company K60.43130.20743475724-42938-1.2203
2024-01-31Fidelity Series Growth Company0.34340.18622767000457001.6793
2023-12-31MS INVF US Growth I0.31860.80752567379522382.0769
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.27090.05982182900498002.3346
2024-01-31Fidelity Extended Market Index0.23010.05181854106321141.7626
2023-12-31Morgan Stanley Insight A0.21561.23311737466818924.9464
2023-12-31Morgan Stanley Insight0.21561.231517374661569949.9334
2024-02-29iShares Russell Mid-Cap Growth ETF0.18980.1154152960200
2024-02-29First Trust Health Care AlphaDEX® ETF0.16471.1673132742600
2024-02-29Transamerica Capital Growth A0.16160.955130236714147612.1868
Total 11.123412.009689637903+1765799+2.0%

3.3. Insider Transactions

Insiders are holding 29.402% of the shares of Roivant Sciences Ltd.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-09Eric VenkerSELL9695010.92
2024-01-02Vivek RamaswamySELL300000011.05
2023-10-05Eric VenkerSELL15302710.11
2023-10-02Eric VenkerSELL44075210.8
2023-10-02Sciences Ltd. RoivantBUY152631638
2023-09-28Keith S ManchesterSELL689614411.55
2023-09-28Svf Investments (uk) LtdSELL1000000012.6
2023-09-27Eric VenkerSELL50000013.02
2023-09-08Eric VenkerSELL10643012.19
2023-09-08Rakhi KumarSELL9935012.18
2023-09-06Eric VenkerSELL592611.85
2023-09-05Rakhi KumarSELL172412
2023-09-01Eric VenkerSELL1476311.9
2023-08-14Eric VenkerSELL5981111.89
2023-08-03Rakhi KumarSELL368112
2023-08-02Eric VenkerSELL1639711.86
2023-08-01Rakhi KumarSELL33612
2023-07-31Eric VenkerSELL11737211.91
2023-07-26Eric VenkerSELL7356810.91
2023-07-24Eric VenkerSELL3308110.93

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Roivant Sciences Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--6.1521.507+308%-0.254+104%0.520+1084%0.520+1084%
Book Value Per Share--7.7973.273+138%2.097+272%2.155+262%2.155+262%
Current Ratio--27.79411.653+139%8.004+247%8.074+244%8.074+244%
Debt To Asset Ratio--0.1000.290-66%0.299-67%0.211-53%0.211-53%
Debt To Equity Ratio--0.1200.567-79%0.503-76%0.361-67%0.361-67%
Dividend Per Share---0.004-100%0.000-100%0.001-100%0.001-100%
Eps--6.0351.313+360%-0.386+106%0.133+4449%0.133+4449%
Free Cash Flow Per Share---0.250-0.257+3%-0.257+3%-0.228-9%-0.228-9%
Free Cash Flow To Equity Per Share--0.031-0.055+280%-0.167+647%-0.087+385%-0.087+385%
Gross Profit Margin--1.0001.134-12%1.105-10%1.064-6%1.064-6%
Intrinsic Value_10Y_max---5.748--------
Intrinsic Value_10Y_min---5.119--------
Intrinsic Value_1Y_max---0.902--------
Intrinsic Value_1Y_min---0.886--------
Intrinsic Value_3Y_max---2.461--------
Intrinsic Value_3Y_min---2.354--------
Intrinsic Value_5Y_max---3.721--------
Intrinsic Value_5Y_min---3.475--------
Market Cap8348564725.760-14%9483304722.5508241414407.198+15%4073551610.880+133%5930926485.375+60%5930926485.375+60%
Net Profit Margin--137.21627.277+403%-40.319+129%-13.149+110%-13.149+110%
Operating Margin---6.197-8.980+45%-33.242+436%-34.640+459%-34.640+459%
Operating Ratio--8.7429.894-12%34.242-74%32.993-74%32.993-74%
Pb Ratio1.329-8%1.4404.582-69%2.506-43%2.859-50%2.859-50%
Pe Ratio0.429-8%0.465-14.613+3241%-3.238+796%-8.236+1870%-8.236+1870%
Price Per Share10.360-8%11.23010.093+11%5.055+122%7.324+53%7.324+53%
Price To Free Cash Flow Ratio-10.375+8%-11.246-9.887-12%-5.053-55%-8.190-27%-8.190-27%
Price To Total Gains Ratio1.684-8%1.825-937.886+51482%-29.117+1695%-332.090+18294%-332.090+18294%
Quick Ratio--27.49711.352+142%7.700+257%7.833+251%7.833+251%
Return On Assets--0.6970.085+721%-0.142+120%-0.042+106%-0.042+106%
Return On Equity--0.8370.022+3771%-0.235+128%-0.094+111%-0.094+111%
Total Gains Per Share--6.1521.510+307%-0.254+104%0.521+1081%0.521+1081%
Usd Book Value--6584582000.0002712985250.000+143%1689528000.000+290%1756670066.667+275%1756670066.667+275%
Usd Book Value Change Per Share--6.1521.507+308%-0.254+104%0.520+1084%0.520+1084%
Usd Book Value Per Share--7.7973.273+138%2.097+272%2.155+262%2.155+262%
Usd Dividend Per Share---0.004-100%0.000-100%0.001-100%0.001-100%
Usd Eps--6.0351.313+360%-0.386+106%0.133+4449%0.133+4449%
Usd Free Cash Flow---210807000.000-209638500.000-1%-207276250.000-2%-184469066.667-12%-184469066.667-12%
Usd Free Cash Flow Per Share---0.250-0.257+3%-0.257+3%-0.228-9%-0.228-9%
Usd Free Cash Flow To Equity Per Share--0.031-0.055+280%-0.167+647%-0.087+385%-0.087+385%
Usd Market Cap8348564725.760-14%9483304722.5508241414407.198+15%4073551610.880+133%5930926485.375+60%5930926485.375+60%
Usd Price Per Share10.360-8%11.23010.093+11%5.055+122%7.324+53%7.324+53%
Usd Profit--5096184000.0001081154500.000+371%-336478500.000+107%106284666.667+4695%106284666.667+4695%
Usd Revenue--37140000.00030810250.000+21%10781750.000+244%15748400.000+136%15748400.000+136%
Usd Total Gains Per Share--6.1521.510+307%-0.254+104%0.521+1081%0.521+1081%
 EOD+3 -5MRQTTM+30 -6YOY+30 -65Y+28 -810Y+28 -8

4.2. Fundamental Score

Let's check the fundamental score of Roivant Sciences Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-150.429
Price to Book Ratio (EOD)Between0-11.329
Net Profit Margin (MRQ)Greater than0137.216
Operating Margin (MRQ)Greater than0-6.197
Quick Ratio (MRQ)Greater than127.497
Current Ratio (MRQ)Greater than127.794
Debt to Asset Ratio (MRQ)Less than10.100
Debt to Equity Ratio (MRQ)Less than10.120
Return on Equity (MRQ)Greater than0.150.837
Return on Assets (MRQ)Greater than0.050.697
Total8/10 (80.0%)

4.3. Technical Score

Let's check the technical score of Roivant Sciences Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.854
Ma 20Greater thanMa 5010.832
Ma 50Greater thanMa 10010.938
Ma 100Greater thanMa 20010.700
OpenGreater thanClose10.400
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Retained Earnings  -3,739,137-33,617-3,772,754-291,816-4,064,570-304,327-4,368,8975,096,184727,287
Income before Tax  -382,077202,861-179,216-146,877-326,093-1,268-327,3615,425,6985,098,337
Net Income  -384,896209,473-175,423-116,393-291,816-12,511-304,3275,400,5115,096,184
Net Income from Continuing Operations  -384,896209,473-175,423-152,422-327,845-3,273-331,1185,403,7835,072,665



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets7,312,679
Total Liabilities728,097
Total Stockholder Equity6,089,763
 As reported
Total Liabilities 728,097
Total Stockholder Equity+ 6,089,763
Total Assets = 7,312,679

Assets

Total Assets7,312,679
Total Current Assets6,806,733
Long-term Assets505,946
Total Current Assets
Cash And Cash Equivalents 6,670,810
Net Receivables 63,188
Inventory 5,240
Other Current Assets 9,688
Total Current Assets  (as reported)6,806,733
Total Current Assets  (calculated)6,748,926
+/- 57,807
Long-term Assets
Property Plant Equipment 68,755
Long Term Investments 239,927
Intangible Assets 150,415
Long-term Assets Other 46,849
Long-term Assets  (as reported)505,946
Long-term Assets  (calculated)505,946
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities244,899
Long-term Liabilities483,198
Total Stockholder Equity6,089,763
Total Current Liabilities
Short-term Debt 56,183
Short Long Term Debt 45,706
Accounts payable 35,226
Other Current Liabilities 148,795
Total Current Liabilities  (as reported)244,899
Total Current Liabilities  (calculated)285,910
+/- 41,011
Long-term Liabilities
Long term Debt 403,337
Capital Lease Obligations 57,536
Long-term Liabilities Other 32,802
Long-term Liabilities  (as reported)483,198
Long-term Liabilities  (calculated)493,675
+/- 10,477
Total Stockholder Equity
Retained Earnings 727,287
Accumulated Other Comprehensive Income -27,784
Other Stockholders Equity 5,390,260
Total Stockholder Equity (as reported)6,089,763
Total Stockholder Equity (calculated)6,089,763
+/-0
Other
Cash and Short Term Investments 6,670,810
Common Stock Shares Outstanding 844,462
Current Deferred Revenue4,695
Liabilities and Stockholders Equity 7,312,679
Net Debt -6,164,231
Net Invested Capital 6,538,806
Net Working Capital 6,561,834
Property Plant and Equipment Gross 68,755
Short Long Term Debt Total 506,579



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
0
2,589,692
2,454,697
3,102,906
2,799,375
2,585,129
2,600,398
2,215,534
2,202,960
2,389,604
2,136,646
2,065,543
7,312,679
7,312,6792,065,5432,136,6462,389,6042,202,9602,215,5342,600,3982,585,1292,799,3753,102,9062,454,6972,589,6920000
   > Total Current Assets 
2,219,245
0
0
0
2,186,995
2,057,609
2,555,754
2,287,533
2,146,523
2,039,442
1,714,861
1,646,232
1,798,587
1,561,158
1,551,627
6,806,733
6,806,7331,551,6271,561,1581,798,5871,646,2321,714,8612,039,4422,146,5232,287,5332,555,7542,057,6092,186,9950002,219,245
       Cash And Cash Equivalents 
0
0
0
0
2,055,044
1,996,733
2,497,330
2,214,283
2,060,400
1,942,215
1,599,021
1,527,437
1,676,813
1,434,093
1,408,231
6,670,810
6,670,8101,408,2311,434,0931,676,8131,527,4371,599,0211,942,2152,060,4002,214,2832,497,3301,996,7332,055,0440000
       Short-term Investments 
0
0
0
0
0
0
0
11,852
13,634
0
0
13,600
15,302
0
0
0
00015,30213,6000013,63411,8520000000
       Net Receivables 
15,279
0
0
0
13,832
5,409
12,316
11,548
6,732
0
27,367
29,454
32,735
39,914
54,624
63,188
63,18854,62439,91432,73529,45427,36706,73211,54812,3165,40913,83200015,279
       Other Current Assets 
4,415
0
0
0
54,250
7,815
2,301
7,834
82,220
93,274
14,180
15,866
121,774
13,004
17,675
9,688
9,68817,67513,004121,77415,86614,18093,27482,2207,8342,3017,81554,2500004,415
   > Long-term Assets 
0
0
0
0
402,697
397,088
547,152
511,842
438,606
560,956
500,673
556,728
591,017
575,488
513,916
505,946
505,946513,916575,488591,017556,728500,673560,956438,606511,842547,152397,088402,6970000
       Property Plant Equipment 
73,932
0
0
0
77,028
80,713
80,102
83,288
86,949
91,118
92,260
91,931
92,337
87,901
73,106
68,755
68,75573,10687,90192,33791,93192,26091,11886,94983,28880,10280,71377,02800073,932
       Long Term Investments 
0
0
0
0
0
280,922
436,780
398,743
325,834
301,287
246,609
272,469
304,317
296,243
250,393
239,927
239,927250,393296,243304,317272,469246,609301,287325,834398,743436,780280,92200000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
145,430
140,298
146,105
144,881
145,037
140,621
150,415
150,415140,621145,037144,881146,105140,298145,430000000000
       Long-term Assets Other 
0
0
0
0
36,128
35,453
30,270
29,811
25,823
23,121
21,506
46,223
49,482
46,307
49,796
46,849
46,84949,79646,30749,48246,22321,50623,12125,82329,81130,27035,45336,1280000
> Total Liabilities 
0
0
0
0
527,687
474,865
652,007
552,113
546,186
822,516
701,385
775,822
782,017
802,507
739,910
728,097
728,097739,910802,507782,017775,822701,385822,516546,186552,113652,007474,865527,6870000
   > Total Current Liabilities 
92,118
0
0
0
218,961
209,158
303,444
160,713
184,367
328,915
230,744
244,255
272,448
245,004
265,546
244,899
244,899265,546245,004272,448244,255230,744328,915184,367160,713303,444209,158218,96100092,118
       Short-term Debt 
0
0
0
0
12,313
12,055
11,518
11,241
11,398
45,162
47,149
49,587
52,413
55,754
59,901
56,183
56,18359,90155,75452,41349,58747,14945,16211,39811,24111,51812,05512,3130000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
33,304
35,754
37,724
40,720
44,406
48,998
45,706
45,70648,99844,40640,72037,72435,75433,304000000000
       Accounts payable 
10,306
0
0
0
20,550
15,014
77,158
24,358
34,583
161,304
41,358
47,999
37,830
50,035
44,123
35,226
35,22644,12350,03537,83047,99941,358161,30434,58324,35877,15815,01420,55000010,306
       Other Current Liabilities 
5,352
0
0
0
180,180
178,312
210,379
120,142
128,239
113,438
133,864
138,873
15,076
128,646
155,724
148,795
148,795155,724128,64615,076138,873133,864113,438128,239120,142210,379178,312180,1800005,352
   > Long-term Liabilities 
0
0
0
0
308,726
265,707
348,563
368,909
339,328
493,601
470,641
531,567
509,569
557,503
474,364
483,198
483,198474,364557,503509,569531,567470,641493,601339,328368,909348,563265,707308,7260000
       Long term Debt Total 
0
0
0
0
0
0
199,869
204,042
210,025
383,720
376,058
375,124
375,515
385,069
0
0
00385,069375,515375,124376,058383,720210,025204,042199,869000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-12,313
65,263
65,221
62,091
62,468
27,091
18,338
17,201
12,756
7,406
-368
1,353
1,353-3687,40612,75617,20118,33827,09162,46862,09165,22165,263-12,3130000
       Warrants
0
0
0
0
0
0
22,491
22,491
22,491
22,491
0
0
0
0
0
0
00000022,49122,49122,49122,491000000
       Long-term Liabilities Other 
0
0
0
0
0
14,094
148,694
164,867
115,563
96,735
82,682
101,518
134,054
172,434
36,289
32,802
32,80236,289172,434134,054101,51882,68296,735115,563164,867148,69414,09400000
       Deferred Long Term Liability 
0
0
0
0
2,300
0
0
0
13,740
13,146
11,901
0
0
0
0
0
0000011,90113,14613,7400002,3000000
> Total Stockholder Equity
0
0
0
0
1,797,788
1,723,122
2,038,015
2,247,262
2,038,943
1,384,111
1,160,601
1,427,138
1,607,587
910,730
948,534
6,089,763
6,089,763948,534910,7301,607,5871,427,1381,160,6011,384,1112,038,9432,247,2622,038,0151,723,1221,797,7880000
   Common Stock
0
0
0
0
0
3,824,974
4,245,860
0
0
0
0
0
0
0
0
0
0000000004,245,8603,824,97400000
   Retained Earnings Total Equity00-4,064,570-3,772,754-3,739,137-3,387,123-3,095,533-2,763,724-2,493,662-2,209,126000000
   Accumulated Other Comprehensive Income 
0
0
0
0
1,445
-1,207
1,281
-1,070
-946
5,020
9,089
-729
-2,617
-6,610
-3,072
-27,784
-27,784-3,072-6,610-2,617-7299,0895,020-946-1,0701,281-1,2071,4450000
   Capital Surplus 
0
0
0
0
0
0
4,245,860
4,360,452
4,421,614
4,474,624
4,538,635
4,695,386
4,933,137
4,981,910
0
0
004,981,9104,933,1374,695,3864,538,6354,474,6244,421,6144,360,4524,245,860000000
   Treasury Stock0000000000000000
   Other Stockholders Equity 
-2,349
0
0
0
3,714,805
3,724,974
4,245,860
4,741,994
4,803,613
4,474,624
4,538,635
5,167,004
5,382,958
4,981,910
5,320,503
5,390,260
5,390,2605,320,5034,981,9105,382,9585,167,0044,538,6354,474,6244,803,6134,741,9944,245,8603,724,9743,714,805000-2,349



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue61,280
Cost of Revenue-13,128
Gross Profit48,15248,152
 
Operating Income (+$)
Gross Profit48,152
Operating Expense-1,125,721
Operating Income-1,077,569-1,077,569
 
Operating Expense (+$)
Research Development525,215
Selling General Administrative600,506
Selling And Marketing Expenses0
Operating Expense1,125,7211,125,721
 
Net Interest Income (+$)
Interest Income32,184
Interest Expense-27,968
Other Finance Cost-0
Net Interest Income4,216
 
Pretax Income (+$)
Operating Income-1,077,569
Net Interest Income4,216
Other Non-Operating Income Expenses56,453
Income Before Tax (EBT)-1,224,834-930,304
EBIT - interestExpense = -1,105,537
-1,224,834
-1,202,056
Interest Expense27,968
Earnings Before Interest and Taxes (EBIT)-1,077,569-1,196,866
Earnings Before Interest and Taxes (EBITDA)-1,107,578
 
After tax Income (+$)
Income Before Tax-1,224,834
Tax Provision-5,190
Net Income From Continuing Ops-1,230,024-1,230,024
Net Income-1,230,024
Net Income Applicable To Common Shares-1,009,030
 
Non-recurring Events
Discontinued Operations114,561
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses1,138,849
Total Other Income/Expenses Net-147,265-60,669
 

Technical Analysis of Roivant
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Roivant. The general trend of Roivant is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Roivant's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Roivant Sciences Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 11.80 < 12.00 < 13.24.

The bearish price targets are: 9.76 > 9.69 > 9.6.

Tweet this
Roivant Sciences Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Roivant Sciences Ltd. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Roivant Sciences Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Roivant Sciences Ltd. The current macd is -0.01542107.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Roivant price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Roivant. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Roivant price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Roivant Sciences Ltd Daily Moving Average Convergence/Divergence (MACD) ChartRoivant Sciences Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Roivant Sciences Ltd. The current adx is 18.65.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Roivant shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Roivant Sciences Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Roivant Sciences Ltd. The current sar is 11.57.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Roivant Sciences Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Roivant Sciences Ltd. The current rsi is 40.85. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Roivant Sciences Ltd Daily Relative Strength Index (RSI) ChartRoivant Sciences Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Roivant Sciences Ltd. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Roivant price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Roivant Sciences Ltd Daily Stochastic Oscillator ChartRoivant Sciences Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Roivant Sciences Ltd. The current cci is -69.55719949.

Roivant Sciences Ltd Daily Commodity Channel Index (CCI) ChartRoivant Sciences Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Roivant Sciences Ltd. The current cmo is -31.48865701.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Roivant Sciences Ltd Daily Chande Momentum Oscillator (CMO) ChartRoivant Sciences Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Roivant Sciences Ltd. The current willr is -87.27272727.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Roivant Sciences Ltd Daily Williams %R ChartRoivant Sciences Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Roivant Sciences Ltd.

Roivant Sciences Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Roivant Sciences Ltd. The current atr is 0.39364462.

Roivant Sciences Ltd Daily Average True Range (ATR) ChartRoivant Sciences Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Roivant Sciences Ltd. The current obv is 25,064,209.

Roivant Sciences Ltd Daily On-Balance Volume (OBV) ChartRoivant Sciences Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Roivant Sciences Ltd. The current mfi is 56.35.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Roivant Sciences Ltd Daily Money Flow Index (MFI) ChartRoivant Sciences Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Roivant Sciences Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-30BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-13ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-06MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Roivant Sciences Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Roivant Sciences Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.854
Ma 20Greater thanMa 5010.832
Ma 50Greater thanMa 10010.938
Ma 100Greater thanMa 20010.700
OpenGreater thanClose10.400
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Roivant with someone you think should read this too:
  • Are you bullish or bearish on Roivant? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Roivant? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Roivant Sciences Ltd

I send you an email if I find something interesting about Roivant Sciences Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Roivant Sciences Ltd.

Receive notifications about Roivant Sciences Ltd in your mailbox!